Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cardiac amyloidosis (CA) is a highly morbid cause of heart failure with a poor untreated prognosis. The presence of left ventricular outflow tract (LVOT) obstruction may lead to misclassification of CA as hypertrophic obstructive cardiomyopathy (HOCM). Between 2022 and 2024, 7 patients-4 with light- chain cardiac amyloidosis (AL-CM) and 3 with transthyretin cardiac amyloidosis-initially presented with HOCM at our center (The Johns Hopkins Hospital, Baltimore, Maryland, USA). Diagnostic delay from HOCM to CA diagnosis ranged from 0 to 34 months. Patients with AL-CM had advanced disease (revised Mayo stage III) at the time of CA diagnosis. Six patients required reduction or withdrawal of therapy used for symptomatic LVOT obstruction, and 3 patients were referred for septal reduction therapy. Screening for CA should be considered in older adult patients presenting with HOCM. Symptomatic management of CA with LVOT obstruction is complex given patients' poor tolerance of negatively inotropic medications and the high burden of orthostatic hypotension in patients with CA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaccas.2025.103946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Initial Results from the Canadian Cardiac Amyloidosis PyrophosphatE Imaging Registry (CAPER).
Can J Cardiol
September 2025
Department of Cardiac Sciences, University of Calgary, Calgary AB, Canada. Electronic address:
Background: Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized cause of heart failure in older adults. Technetium-99m pyrophosphate (PYP) imaging has emerged as a highly effective tool for diagnosing ATTR-CM. We established a multi-center Canadian registry to provide a platform for research regarding the prevalence of ATTR-CM and accuracy of methods for screening or diagnosis.
View Article and Find Full Text PDFTransthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure.
JAMA Cardiol
September 2025
Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York.
Importance: Transthyretin cardiac amyloidosis (ATTR-CA) is an underdiagnosed but treatable cause of heart failure (HF) in older individuals that occurs in the context of normal wild-type (ATTRwt-CA) or an abnormal inherited (ATTRv-CA) TTR gene variant. While the most common inherited TTR variant, V142I, occurs in 3% to 4% of self-identified Black Americans and is associated with excess morbidity and mortality, the prevalence of ATTR-CA in this at-risk population is unknown.
Objective: To define the prevalence of ATTR-CA and proportions attributable to ATTRwt-CA or ATTRv-CA among older Black and Caribbean Hispanic individuals with HF.
Clinical experience of a systemic algorithm for diagnosis of cardiac amyloidosis.
Dan Med J
August 2025
Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital.
Introduction: Cardiac amyloidosis is an underdiagnosed disease, and its prevalence is probably higher than previously estimated. We aimed to investigate the effect of introducing a systemic diagnostic algorithm for cardiac amyloidosis in clinical practice.
Methods: A systematic diagnostic algorithm was developed and clinically applied in two hospitals in Eastern Denmark.
Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702).
Blood
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.
View Article and Find Full Text PDFOutcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias.
Heart Rhythm O2
August 2025
Cardiac Electrophysiology Section, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Background: Cardiac amyloidosis (CA) is characterized by atrial myopathy, which predisposes patients to atrial fibrillation (AF) and other atrial arrhythmias (AA). Although catheter ablation of AA is effective in the general population, its efficacy and safety in patients with CA remain unclear.
Objective: The study aimed to evaluate outcomes in patients with CA undergoing catheter ablation for typical atrial flutter (TAFL) and left atrial (LA) arrhythmias and to assess the presence and influence of LA low-voltage areas (LVA) in the latter.